<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of chronic hepatitis C infection in adults with kidney function impairment</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of chronic hepatitis C infection in adults with kidney function impairment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of chronic hepatitis C infection in adults with kidney function impairment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael D Leise, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lionel Rostaing, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adrian M Di Bisceglie, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Fernando C Fervenza, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allyson Bloom, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 18, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1907695803"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chronic hepatitis C virus (HCV) infection is frequently present in patients with kidney function impairment. There is a strong and likely causal association between chronic HCV infection and glomerular disease, including mixed cryoglobulinemia, membranoproliferative glomerulonephritis, and possibly membranous nephropathy [<a href="#rid1">1</a>]. HCV has also been associated with proteinuria, incident chronic kidney disease (CKD), progressive CKD, and end-stage kidney disease (ESKD) in general population cohorts [<a href="#rid2">2</a>]. In addition, the prevalence of anti-HCV antibody is higher among patients on hemodialysis compared with healthy populations, suggesting that dialysis patients may be at higher risk of acquiring HCV infection. (See  <a class="medical medical_review" href="/z/d/html/1861.html" rel="external">"Hepatitis C virus infection in patients on maintenance dialysis", section on 'Epidemiology'</a>.)</p><p>The management of HCV in adults with significant kidney disease (ie, estimated glomerular filtration rate &lt;30 mL/min per 1.73 m<sup>2</sup>) has undergone substantial changes with the availability of new direct-acting antiviral agents. New HCV medications have allowed for interferon-free and, in almost all cases, ribavirin-free treatment regimens. </p><p>This topic will discuss the approach to antiviral therapy of patients with HCV infection and kidney function impairment. Other management issues, such as consideration for immunosuppressive therapy of HCV-associated renal disease as well as treatment of proteinuria and hypertension or other complications, may also be important in such patients. Discussions of renal disease associated with HCV infection, the epidemiology and prevention of HCV infection among dialysis patients, and HCV infection associated with kidney transplantation are found in detail elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3065.html" rel="external">"Overview of kidney disease associated with hepatitis C virus infection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3062.html" rel="external">"Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/3070.html" rel="external">"Mixed cryoglobulinemia syndrome: Treatment and prognosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1861.html" rel="external">"Hepatitis C virus infection in patients on maintenance dialysis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7310.html" rel="external">"Hepatitis C infection in kidney transplant candidates and recipients"</a>.)</p><p></p><p class="headingAnchor" id="H4098504099"><span class="h1">ANTIVIRAL TREATMENT</span></p><p class="headingAnchor" id="H1907695881"><span class="h2">Rationale for antiviral treatment</span><span class="headingEndMark"> — </span>The primary rationale for antiviral treatment in patients with chronic HCV infection is to prevent liver-related morbidity and mortality. In the patient with advanced chronic kidney disease (CKD) who is a potential kidney transplant candidate, an additional reason is to prevent kidney transplant-related complications specific to HCV infection. In the less common scenario of HCV-associated vasculitis and/or glomerulonephritis (such as mixed cryoglobulinemia), an additional objective is to eradicate the immunologic stimulus (ie, HCV itself) for the vasculitis and/or glomerulonephritis.</p><p>The main sequelae of chronic HCV infection usually develop over the span of decades and include cirrhosis and hepatocellular carcinoma. Eradication of HCV prior to the development of decompensated cirrhosis results in decreased all-cause mortality, liver-related death, need for liver transplantation, hepatocellular carcinoma rates, and liver-related complications [<a href="#rid3">3-8</a>]. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15832.html" rel="external">"Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection", section on 'Benefits of treatment'</a>.)</p><p>For patients with HCV-associated renal disease, cure of HCV confers additional benefits. As examples, in several earlier studies of patients with HCV-associated membranoproliferative glomerulonephritis and/or mixed cryoglobulinemia, improvements in the cutaneous vasculitis, cryoglobulin titers, proteinuria, and the plasma creatinine concentration were observed in the majority patients who achieved HCV viral suppression during interferon-based treatment [<a href="#rid9">9-23</a>]. In one study of 14 patients, protein excretion fell among viral responders from 6.1 to 1.3 g/day, while there was a lesser, non-statistically significant reduction in protein excretion in nonresponders (6.1 versus 4.2 g/day) [<a href="#rid12">12</a>]. Cessation of interferon therapy resulted in recurrence of viremia, which coincided with recurrent vasculitis, in most patients in these studies, suggesting that the efficacy of interferon was directly related to its antiviral activity [<a href="#rid9">9,11,12,14,24</a>]. In general, when patients with mixed cryoglobulinemia and HCV are treated for HCV and achieve a sustained virologic response, the mixed cryoglobulinemia and its renal manifestations usually (but not always) resolve [<a href="#rid25">25</a>]. As the treatment paradigm for HCV infection has moved away from interferon-containing regimens in all patients, including those with kidney disease and mixed cryoglobulinemia, case reports and series have emerged demonstrating the efficacy of newer direct-acting antiviral (DAA) agents in the treatment of HCV and mixed cryoglobulinemia [<a href="#rid26">26-29</a>].</p><p class="headingAnchor" id="H1907695888"><span class="h2">Patient selection for treatment</span><span class="headingEndMark"> — </span>We agree with the guidelines from the American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA) that recommend treatment for all patients with chronic HCV infection who have access to DAA therapies, including those who have kidney function impairment and/or are on dialysis; the main exceptions to universal treatment are patients with short life expectancies due to comorbidities [<a href="#rid30">30</a>]. </p><p>Specific considerations regarding life expectancy are warranted for patients with HCV-related renal disease and those with severe renal impairment (ie, with estimated glomerular filtration rate [eGFR] &lt;30 mL/min per 1.73 m<sup>2</sup> or on dialysis):</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with HCV-related renal disease, successful antiviral treatment is likely to result in improved renal function and symptoms related to renal failure. Thus, we believe that antiviral treatment is warranted in such patients, even if life expectancy may otherwise be limited due to other comorbidities. Some of these patients may also warrant immunosuppressive therapy, and timing of antiviral therapy in relation to immunosuppression is an important management consideration. (See <a class="local">'Timing of treatment'</a> below and <a class="local">'Rationale for antiviral treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who have severe renal impairment or are on dialysis and have incidental HCV infection (ie, the renal disease is not associated with HCV), the decision on antiviral treatment should be undertaken on a case-by-case basis and take into account the potential for kidney transplant candidacy in addition to the anticipated benefits of HCV therapy, comorbidities, and life expectancy. In many cases, such individuals have significant comorbidities, including cardiovascular disease. With advanced CKD and competing comorbidities, it can be difficult to determine whether treatment of chronic HCV infection would actually provide the patient with a meaningful benefit. HCV treatment is warranted for most patients who are kidney transplant candidates, although the timing of treatment in relation to transplantation depends on various factors that are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7310.html" rel="external">"Hepatitis C infection in kidney transplant candidates and recipients", section on 'Timing of treatment'</a>.)</p><p></p><p class="bulletIndent1">Decisions to treat patients with severe renal impairment and decompensated cirrhosis (eg, ascites, hepatic synthetic dysfunction, or hepatic encephalopathy) are further complicated, as most treatment trials of patients with decompensated cirrhosis have excluded those with eGFR &lt;40 mL/min per 1.73 m<sup>2 </sup>[<a href="#rid31">31</a>]. Furthermore, antiviral options are more limited in this population. Specifically, HCV protease inhibitors are contraindicated in decompensated cirrhosis. These patients should be managed by an expert in the care of such patients, preferably at a transplant center. (See <a class="local">'Hepatorenal syndrome'</a> below.)</p><p></p><p>The approach to deciding on antiviral treatment for patients with kidney disease has evolved. Prior to the availability of DAA agents that could be safely used in patients with kidney disease, including those on dialysis, deciding to treat these patients represented a management challenge. With non-DAA-based regimens (ie, standard or pegylated interferon with or without <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a>), the efficacy of antiviral therapy was suboptimal, and the potential toxicity of therapy was high, depending on the extent of renal impairment and the comorbid conditions. With the growing availability of DAAs that can be used safely in patients with kidney disease, including those on dialysis, the decision to treat HCV infection in these patients has become less challenging. </p><p class="headingAnchor" id="H1907695895"><span class="h2">Timing of treatment</span><span class="headingEndMark"> — </span>The timing of antiviral therapy is relevant for patients who have HCV-associated renal disease as well as for patients with advanced CKD awaiting transplant. </p><p class="headingAnchor" id="H602866320"><span class="h3">Patients with HCV-associated renal disease</span><span class="headingEndMark"> — </span>For patients with severe, acute vasculitic manifestations associated with HCV infection, immunosuppressive therapy may be warranted in addition to antiviral therapy. We initiate immunosuppressive therapy first and delay antiviral therapy for one to four months. This approach is in agreement with the European Alliance of Associations for Rheumatology (EULAR; formerly known as European League Against Rheumatism) and the Italian Group for the Study of Cryoglobulinemias guidelines [<a href="#rid32">32-34</a>]. Immunosuppressive therapy is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3065.html" rel="external">"Overview of kidney disease associated with hepatitis C virus infection"</a> and  <a class="medical medical_review" href="/z/d/html/3070.html" rel="external">"Mixed cryoglobulinemia syndrome: Treatment and prognosis", section on 'Moderate to severe disease'</a>.)</p><p>Although recommendations from these expert groups were formulated prior to the availability of newer DAA agents, there are still limited data on the efficacy and safety of these agents with concomitant use of potent immunosuppressive therapy. Thus, we continue to favor initiation of immunosuppression for severe vasculitic sequelae and/or HCV-related renal disease before starting antiviral medications.</p><p>The rationale for delaying antiviral therapy by one to four months in patients who require immunosuppressive therapy is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Immunosuppressive therapy can rapidly improve inflammation and resolve target organ damage. Clinical improvements due to antiviral therapy are gradual. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High-dose immunosuppressive therapy and antiviral therapy each have side effects. Thus, patients may not be able to tolerate both treatments simultaneously. This rationale is less important for interferon-free and ribavirin-free regimens. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD19+ B cell depletion with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> reduces the viral "reservoir" in CD19+ B cells. </p><p></p><p class="headingAnchor" id="H602866359"><span class="h3">Kidney transplant candidates</span><span class="headingEndMark"> — </span>Whether to treat HCV infection in kidney transplant candidates prior to or after transplantation is a major management decision, and the optimal approach is uncertain. Kidney transplant should not be withheld from candidates with untreated HCV infection, as post-transplantation treatment with DAA therapy is effective and safe. </p><p>Decisions on timing of antiviral treatment depend upon several factors, including severity of liver disease, extrahepatic complications of HCV infection, anticipated wait time on the transplant list, and accessibility of HCV-positive donor organs. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7310.html" rel="external">"Hepatitis C infection in kidney transplant candidates and recipients", section on 'Timing of treatment'</a>.)</p><p class="headingAnchor" id="H2766804422"><span class="h2">Regimen selection and dosing</span><span class="headingEndMark"> — </span>The selection of the antiviral regimen among patients with renal disease is largely the same as that among patients without renal disease and depends on genotype, extent of underlying liver disease, and treatment history. </p><p>In general, <a class="drug drug_general" data-topicid="114296" href="/z/d/drug information/114296.html" rel="external">glecaprevir-pibrentasvir</a> and <a class="drug drug_general" data-topicid="108951" href="/z/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> are the main pangenotypic options for initial HCV treatment  (<a class="graphic graphic_algorithm graphicRef93587" href="/z/d/graphic/93587.html" rel="external">algorithm 1</a>). Details on regimen specifics (eg, the duration of therapy), treatment of relapsed infections, and alternative regimens are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16592.html" rel="external">"Management of chronic hepatitis C virus infection: Initial antiviral therapy in adults"</a> and  <a class="medical medical_review" href="/z/d/html/15795.html" rel="external">"Management of chronic hepatitis C virus infection: Antiviral retreatment following relapse in adults"</a>.)</p><p>Dose adjustments of the DAAs that can be used in advanced renal disease and hemodialysis are not necessary. However, sofosbuvir-containing regimens are cleared by dialysis and should be administered after the session on hemodialysis days. Dosing data among patients on peritoneal dialysis are limited. </p><p>However, in the uncommon case that <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> is used for treatment in such patients, the dose is adjusted depending on renal function (see <a class="local">'Ribavirin'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with an eGFR &lt;50 but ≥30 mL/min per 1.73 m<sup>2</sup>, it is given orally at alternating doses of 200 and 400 mg every other day. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with an eGFR &lt;30 mL/min per 1.73 m<sup>2</sup> or on dialysis, use of <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> is controversial because of the risk of hemolysis. We use it with caution and at an initial low dose of 200 mg three times weekly. Additionally, for patients with a pre-treatment hemoglobin level &lt;10 g/dL, we pre-emptively administer adjunctive erythropoietin therapy during the course of ribavirin if the patient is not already taking it. For patients without pre-existing anemia, a reasonable alternative is to start ribavirin therapy without adjunctive erythropoietin but have a low threshold to initiate it if there is any decrease in hemoglobin. (See <a class="local">'Ribavirin'</a> below.)</p><p></p><p>The eGFR can be calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [<a href="#rid35">35</a>]. This equation is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2359.html" rel="external">"Assessment of kidney function"</a>.) </p><p>Although there is an overall paucity of data on anti-HCV therapy in patients with renal disease, there is growing evidence on the use of various regimens in such patients. In general, contemporary antiviral regimens have high efficacy in patients with renal disease, similar to that in the general population, and are safe overall. (See <a class="local">'Antiviral efficacy and safety'</a> below.)</p><p class="headingAnchor" id="H3624177005"><span class="h2">Care team</span><span class="headingEndMark"> — </span>A multidisciplinary approach, with a nephrologist and a hepatologist who have experience treating these complex issues, may improve care for patients with HCV and renal impairment. If HCV-associated cryoglobulinemic vasculitis (such as mixed cryoglobulinemia) is present, the care team may also include a rheumatologist.</p><p class="headingAnchor" id="H1907695944"><span class="h1">ANTIVIRAL EFFICACY AND SAFETY</span></p><p class="headingAnchor" id="H2727325113"><span class="h2">Direct-acting antivirals</span><span class="headingEndMark"> — </span>Data evaluating the use of direct-acting antiviral (DAA) agents in patients with significant renal impairment are accumulating, although these remain more limited than for the general population. Furthermore, there are no data directly comparing the efficacy of antiviral therapy in patients with and without significant renal impairment. Nevertheless, available evidence in patients with eGFR &lt;30 mL/min per 1.73 m<sup>2</sup> or on dialysis suggests comparably high efficacy as seen in the general population. Many DAAs also largely appear safe in patients with renal impairment, including those on dialysis. In the absence of direct safety data for certain agents, assumptions about expected safety can also be made based on the mechanism of metabolism.</p><p><a class="drug drug_general" data-topicid="114296" href="/z/d/drug information/114296.html" rel="external">Glecaprevir-pibrentasvir</a> and sofosbuvir-containing regimens are the primary treatment options for most patients with HCV infection. </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="114296" href="/z/d/drug information/114296.html" rel="external">Glecaprevir-pibrentasvir</a> – Both glecaprevir and pibrentasvir undergo hepatic metabolism and clearance, and levels are largely unaffected by renal impairment. In a study (EXPEDITION-4) of 104 patients with genotypes 1 through 6 infection and estimated glomerular filtration rate (eGFR) &lt;30 mL/min per 1.73 m<sup>2</sup>, 82 percent of whom were on dialysis, 98 percent achieved sustained virologic response (SVR) with glecaprevir-pibrentasvir for 12 weeks [<a href="#rid36">36</a>]. Twenty percent had compensated cirrhosis. The regimen was generally well tolerated. None of the severe adverse events were considered drug related, but four percent of patients discontinued the regimen because of adverse events.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sofosbuvir-containing combinations</strong> – The major elimination pathway for <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a> is renal, so exposure to the drug is increased in patients with severe renal impairment [<a href="#rid37">37</a>]. Because of this and some data suggesting worsening renal function with sofosbuvir, sofosbuvir-containing regimens were previously only recommended for patients with eGFR &gt;30 mL/min per 1.73 m<sup>2</sup>. However, based on subsequent evidence indicating safety, the US Food and Drug Administration approved sofosbuvir-containing regimens for use in severe renal impairment and dialysis in 2019 [<a href="#rid38">38</a>]. It does not appear that the dose of sofosbuvir needs to be adjusted for renal function. Other antiviral agents that are used in combination with sofosbuvir (eg, velpatasvir, ledipasvir, and voxilaprevir) are all hepatically cleared, and their levels are largely unaffected by renal impairment.</p><p></p><p class="bulletIndent1">In a study of 59 patients with end-stage kidney diseases on dialysis and genotypes 1 to 6 HCV infection, <a class="drug drug_general" data-topicid="108951" href="/z/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> (400 mg to 100 mg) for 12 weeks resulted in an SVR rate of 95 percent [<a href="#rid39">39</a>]. Serious adverse events were reported in 19 percent, but all were thought to be unrelated to the treatment; the only renal adverse events were urinary frequency in one patient and an episode of renal colic. Although <a class="drug drug_general" data-topicid="97562" href="/z/d/drug information/97562.html" rel="external">ledipasvir-sofosbuvir</a> and <a class="drug drug_general" data-topicid="114088" href="/z/d/drug information/114088.html" rel="external">sofosbuvir-velpatasvir-voxilaprevir</a> have not been specifically studied in trials of patients with renal impairment, their safety is thought to be comparable to that of sofosbuvir-velpatasvir because of the pharmacodynamics. </p><p></p><p class="bulletIndent1">Observational studies have also suggested generally safe use of various sofosbuvir-containing regimens in patients with renal impairment [<a href="#rid40">40-44</a>]. Some, however, have suggested that advanced chronic kidney disease is associated with a higher risk of acute kidney injury with sofosbuvir-containing regimens [<a href="#rid45">45-47</a>].</p><p></p><p>Other regimens that are less frequently used but have documented efficacy and safety in the setting of renal impairment include: </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="106574" href="/z/d/drug information/106574.html" rel="external">Elbasvir-grazoprevir</a> – Several studies have documented that elbasvir-grazoprevir safely results in high SVR rates in patients with renal impairment [<a href="#rid48">48,49</a>]. As an example, in a study (C-SURFER) that included 122 genotype 1-infected patients with eGFR &lt;30 mL/min per 1.73 m<sup>2</sup>, three-quarters of whom were on dialysis, 94 percent achieved SVR with elbasvir-grazoprevir for 12 weeks [<a href="#rid48">48</a>]. The regimen was generally well tolerated, and the frequency of adverse events was comparable to that in a placebo control group. None of the participants who received elbasvir-grazoprevir discontinued therapy for adverse effects, although one episode of congestive heart failure was ultimately attributed to the drug. The role of elbasvir-grazoprevir in the treatment of genotype 1 infection is discussed in detail elsewhere. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="98762" href="/z/d/drug information/98762.html" rel="external">Ombitasvir-paritaprevir-ritonavir plus dasabuvir</a> – This regimen also appears effective and safe in severe renal impairment. In a study (RUBY-1) of genotype 1-infected patients with eGFR &lt;30 mL/min per 1.73 m<sup>2</sup>, including those on dialysis and without cirrhosis, a 12-week regimen of ombitasvir-paritaprevir-ritonavir plus dasabuvir (with <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> added for subtype 1a infection) resulted in an SVR12 of 90 percent [<a href="#rid50">50</a>]. Most adverse events were mild or moderate, and there were no regimen discontinuations. However, as expected, the genotype 1a-infected patients who received ribavirin had more frequent side effects that were likely directly related to the ribavirin, including anemia and fatigue (see <a class="local">'Ribavirin'</a> below). The role of ombitasvir-paritaprevir-ritonavir plus dasabuvir in the treatment of genotype 1 infection is discussed in detail elsewhere. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Daclatasvir</strong> – Daclatasvir is primarily metabolized by the liver, and renal elimination is minor. A pharmacologic analysis did not identify clinically important increases in daclatasvir levels among patients with eGFR ≤30 mL/min per 1.73 m<sup>2 </sup>or on dialysis [<a href="#rid51">51</a>]. Daclatasvir is usually given with <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a> in locations with limited access to more commonly used regimens. </p><p></p><p class="headingAnchor" id="H1732499683"><span class="h2">Ribavirin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">Ribavirin</a> is not commonly used in HCV antiviral therapy, although there are rare indications for adding it to a DAA regimen. (See <a class="local">'Regimen selection and dosing'</a> above.)</p><p>The main adverse effect of <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> is hemolytic anemia, and the risk is predicted by ribavirin plasma concentration [<a href="#rid52">52</a>]. Since ribavirin is cleared mainly via the kidney, and very little ribavirin is removed with hemodialysis, the drug accumulates and can cause severe anemia in patients with renal insufficiency [<a href="#rid53">53</a>]. Even at lower doses, ribavirin may result in catastrophic anemia in patients with renal impairment. </p><p>Thus, the use of <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> in moderate to severe renal insufficiency is controversial. The manufacturer of one brand of ribavirin (Rebetol) has issued warnings for patients with renal dysfunction and contraindicated its use with creatinine clearance &lt;50 mL/min [<a href="#rid54">54,55</a>]. However, a different brand of ribavirin (Copegus) is approved in the United States for patients with end-stage kidney disease and those on hemodialysis [<a href="#rid56">56</a>].</p><p>We cautiously use <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> in patients with moderate to severe renal impairment, including those on hemodialysis, with low starting doses, closer monitoring of the hemoglobin level, aggressive ribavirin dose reductions for anemia, and adjunctive use of erythropoietic growth factors. (See <a class="local">'Regimen selection and dosing'</a> above.)</p><p>This practice is supported by several studies that have reported overall safe use of <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> despite anemia in patients with moderate to severe renal insufficiency when such measures are taken, although treatment interruptions may be necessary. In a trial of <a class="drug drug_general" data-topicid="98762" href="/z/d/drug information/98762.html" rel="external">ombitasvir-paritaprevir-ritonavir plus dasabuvir</a> among patients with eGFR &lt;30 mL/min per 1.73 m<sup>2</sup>, ribavirin dosed at 200 mg daily was added in 13 patients [<a href="#rid50">50</a>]. Ribavirin use was suspended for meeting prespecified hemoglobin criteria (&gt;2 g/dL drop in four weeks or a level &lt;10 g/dL) in 69 percent (9 patients). Four patients required erythropoietin-stimulating agents, but none required blood transfusions, and there were no serious adverse events deemed associated with therapy. Three patients were able to restart ribavirin. </p><p>Earlier trials had also suggested relatively safe, cautious use of <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> in this population, despite the higher rate of anemia. In a randomized trial of peginterferon with ribavirin (200 mg daily) versus peginterferon alone in 205 Asian patients with HCV on hemodialysis, patients receiving peginterferon and ribavirin were more likely to have significant anemia (defined as hemoglobin &lt;8.5 g/dL) that warranted reduction of ribavirin dose (72 versus 6 percent) and used a higher mean erythropoietin dose (13,946 versus 6449 international units) compared with those who received only peginterferon [<a href="#rid18">18,57-59</a>]. Eleven patients who received combination therapy had nadir hemoglobin concentrations &lt;7.5 g/dL, although only one patient in each group required transfusion. The difference in adverse event-related withdrawal rates (7 percent for combination therapy versus 4 percent for monotherapy) was not statistically significant. </p><p class="headingAnchor" id="H1082694534"><span class="h1">MONITORING OF PATIENTS ON ANTIVIRAL THERAPY</span><span class="headingEndMark"> — </span>The frequency of monitoring patients on antiviral treatment is dependent upon multiple variables including, but not limited to: </p><p class="bulletIndent1"><span class="glyph">●</span>The HCV treatment regimen selected</p><p class="bulletIndent1"><span class="glyph">●</span>The severity of renal impairment</p><p class="bulletIndent1"><span class="glyph">●</span>The presence of HCV-associated renal disease (such as cryoglobulinemia) and its severity</p><p class="bulletIndent1"><span class="glyph">●</span>The presence of cirrhosis </p><p class="bulletIndent1"><span class="glyph">●</span>The presence of other comorbidities (including hepatitis B virus coinfection)</p><p></p><p>The specific monitoring parameters for patients with renal impairment are largely the same as those for the general population, which are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3673.html" rel="external">"Overview of the management of chronic hepatitis C virus infection", section on 'Monitoring during antiviral therapy'</a>.)</p><p>There are a few additional considerations for patients with renal impairment:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients using a sofosbuvir-containing regimen, we check blood urea nitrogen (BUN) and creatinine every two weeks throughout the course of therapy because of the possibility of acute kidney injury in patients with chronic kidney disease [<a href="#rid45">45,46</a>]. We consider discontinuing the sofosbuvir-containing regimen if the eGFR decreases by more than 25 percent in the absence of other cause. (See <a class="local">'Direct-acting antivirals'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients on hemodialysis receiving <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a>, we check a weekly complete blood count throughout the course of therapy because of the greater risk of anemia in such patients. (See <a class="local">'Ribavirin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who have mixed cryoglobulinemia, blood specimens for viral load testing may require special handling to prevent falsely low measurements. HCV viral particles may be incorporated into the cryoprecipitate and centrifuged during preparation of serum samples or may precipitate from the serum during storage. To ensure accurate quantitation of the HCV viral load, specimens should be kept at 37 degrees centigrade during serum preparation, and any cryoprecipitate should be dissolved or suspended into the serum before measuring the viral load.</p><p></p><p class="headingAnchor" id="H26025979"><span class="h1">RECOMMENDATIONS OF OTHERS</span><span class="headingEndMark"> — </span>Several guidelines are available that discuss management of chronic HCV infection in patients with kidney disease. </p><p>In 2014, guidelines for the diagnosis and management of HCV infection were released jointly by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) [<a href="#rid60">60</a>]. These are continuously updated and can be accessed at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.hcvguidelines.org%2F&amp;token=sL%2Bp%2BgWoM5K8OZ3TcR7z2aLRyWCGNBK9vbXZNzy9A7wOhWa41Lo4fh2xvvlb%2BhyX&amp;TOPIC_ID=93448" target="_blank">www.hcvguidelines.org</a> [<a href="#rid60">60</a>]. </p><p>The Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines for hepatitis C in chronic kidney disease were updated in 2022 [<a href="#rid61">61</a>]. These recommend that all patients with chronic kidney disease and HCV infection be evaluated for antiviral therapy, and they recommend an interferon-free regimen for treatment. </p><p>Links to these and other guidelines are found below. (See <a class="local">'Society guideline links'</a> below.)</p><p class="headingAnchor" id="H26027538"><span class="h1">SPECIFIC CONSIDERATIONS</span></p><p class="headingAnchor" id="H1907704959"><span class="h2">Kidney transplant recipients</span><span class="headingEndMark"> — </span>Any antiviral treatment for HCV infection in renal transplant recipients should only be undertaken by clinicians with experience in caring for such patients. Management of such patients is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7310.html" rel="external">"Hepatitis C infection in kidney transplant candidates and recipients", section on 'Monitoring after transplantation'</a>.)</p><p class="headingAnchor" id="H885581843"><span class="h2">Hepatorenal syndrome</span><span class="headingEndMark"> — </span>Patients with cirrhosis who develop hepatorenal syndrome (I or II) with MELDNa scores ≥20 are generally not candidates for HCV antiviral therapy, and it is not recommended at this time. Patients with hepatorenal syndrome type 1 should be considered for liver transplantation referral. Patients with either form of hepatorenal syndrome generally have advanced liver disease with portal hypertensive complications and a poor prognosis. While data from trials (SOLAR-1,SOLAR-2, and ASTRAL-4) support the efficacy and safety of <a class="drug drug_general" data-topicid="97562" href="/z/d/drug information/97562.html" rel="external">ledipasvir-sofosbuvir</a> and velpatasvir-sofosbuvir in patients with Child-Pugh B and C cirrhosis, these trials excluded patients with creatinine clearance &lt;40 mL/min per 1.73 m<sup>2 </sup>[<a href="#rid62">62-64</a>]. Patients who are transplant candidates should have their HCV infection treated post-liver transplantation. (See <a class="local">'Liver transplant recipients'</a> below.)</p><p>The hepatorenal syndrome is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2308.html" rel="external">"Hepatorenal syndrome"</a>.)</p><p class="headingAnchor" id="H885581859"><span class="h2">Liver transplant recipients</span><span class="headingEndMark"> — </span>Liver transplant recipients are at risk for declining renal function over time. In the largest study on this topic, 18 percent of liver transplant recipients had renal dysfunction (estimated glomerular filtration rate [eGFR] &lt;30 mL/min per 1.73 m<sup>2</sup>)<sup> </sup>five years after transplantation [<a href="#rid65">65</a>]. Risk factors for post-liver transplant renal disease include pre-transplant renal dysfunction, perioperative renal failure, early allograft dysfunction, infections, and most importantly, calcineurin inhibitors. The management of renal disease in such patients is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4589.html" rel="external">"Liver transplantation in adults: Long-term management of transplant recipients", section on 'Acute and chronic renal disease'</a>.)</p><p>Post-liver transplant antiviral treatment should be performed by experienced providers at a transplant center. We agree with the joint guidelines from the American Association for the Study of Liver Disease (AASLD) and the Infectious Diseases Society of America (IDSA) that recommend a direct-acting antiviral-based regimen for liver transplant recipients [<a href="#rid60">60</a>]. The specific regimens depend on HCV genotype and are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4583.html" rel="external">"Hepatitis C virus infection in liver transplant candidates and recipients", section on 'Post-transplant antiviral therapy'</a>.)</p><p>However, certain dose or regimen modifications may be warranted in liver transplant recipients who also have renal impairment. Those who have eGFR between 30 and 50 mL/min per 1.73 m<sup>2</sup> can be treated with the same regimens recommended for the general liver transplant population, although if <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> is used, the daily dose should be 200 mg alternating with 400 mg. </p><p class="headingAnchor" id="H2653783988"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113060.html" rel="external">"Society guideline links: Hepatitis C virus infection"</a>.)</p><p class="headingAnchor" id="H1907708115"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale for antiviral treatment</strong> – The primary rationale for antiviral treatment in patients with chronic hepatitis C virus (HCV) infection is to prevent liver-associated morbidity and mortality. Additional reasons specific to patients with renal impairment are to prevent subsequent graft complications in kidney transplant candidates and to eradicate the immunologic stimulus in those who have HCV-related vasculitis or glomerulonephritis. (See <a class="local">'Rationale for antiviral treatment'</a> above and  <a class="medical medical_review" href="/z/d/html/15832.html" rel="external">"Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection", section on 'Benefits of treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for treatment</strong> – We recommend antiviral treatment for all patients with chronic HCV infection, including those with severe renal impairment, who have access to direct-acting antiviral (DAA) therapies and do not have short life expectancies due to comorbidities (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). For patients with HCV-related renal disease (eg, mixed cryoglobulinemia), we suggest antiviral treatment even if life expectancy is limited to improve renal function and symptoms (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). In other patients with limited life expectancies, the decision to treat should be individualized and depends on comorbidities and the potential for kidney transplant candidacy. (See <a class="local">'Patient selection for treatment'</a> above and <a class="local">'Rationale for antiviral treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing of treatment in selected populations</strong> – For patients with severe, acute, HCV-associated vasculitic manifestations that warrant immunosuppressive therapy, we suggest initiating immunosuppressive therapy first and delaying antiviral therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We typically delay antiviral therapy for one to four months. (See <a class="local">'Timing of treatment'</a> above.)</p><p></p><p class="bulletIndent1">For kidney transplant candidates, the timing of antiviral treatment relative to transplant depends upon several factors, including severity of liver disease, extrahepatic complications of HCV infection, anticipated wait time on the transplant list, and accessibility of HCV-positive donor organs. (See <a class="local">'Kidney transplant candidates'</a> above and  <a class="medical medical_review" href="/z/d/html/7310.html" rel="external">"Hepatitis C infection in kidney transplant candidates and recipients", section on 'Timing of treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiviral selection</strong> – The selection of the antiviral regimen among patients with renal disease is largely the same as that among patients without renal disease. In general, <a class="drug drug_general" data-topicid="114296" href="/z/d/drug information/114296.html" rel="external">glecaprevir-pibrentasvir</a> and <a class="drug drug_general" data-topicid="108951" href="/z/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> are the preferred pangenotypic options for initial treatment  (<a class="graphic graphic_algorithm graphicRef93587" href="/z/d/graphic/93587.html" rel="external">algorithm 1</a>). Accumulating data suggest that commonly used DAA regimens are safe and have high efficacy among patients with severe renal impairment. (See <a class="local">'Regimen selection and dosing'</a> above and <a class="local">'Antiviral efficacy and safety'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing considerations</strong> – No dose adjustments are warranted for DAA agents in patients with severe renal impairment or on dialysis. <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">Ribavirin</a> is rarely warranted, but if indicated, it is dose-reduced for renal function and used with close monitoring for anemia; patients with more severe renal impairment may additionally warrant adjunctive erythropoietic stimulating agents. (See <a class="local">'Regimen selection and dosing'</a> above and <a class="local">'Ribavirin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – We check blood urea nitrogen (BUN) and creatinine every two weeks in patients with renal impairment taking a sofosbuvir-containing regimen. Otherwise, monitoring during antiviral treatment is largely the same as for the general population. (See  <a class="medical medical_review" href="/z/d/html/3673.html" rel="external">"Overview of the management of chronic hepatitis C virus infection", section on 'Monitoring during antiviral therapy'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sandri AM, Elewa U, Poterucha JJ, Fervenza FC. Treatment of hepatitis C-mediated glomerular disease. Nephron Clin Pract 2011; 119:c121.</a></li><li><a class="nounderline abstract_t">Henson JB, Sise ME. The association of hepatitis C infection with the onset of CKD and progression into ESRD. Semin Dial 2019; 32:108.</a></li><li><a class="nounderline abstract_t">Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52:833.</a></li><li><a class="nounderline abstract_t">Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147:677.</a></li><li><a class="nounderline abstract_t">van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308:2584.</a></li><li><a class="nounderline abstract_t">Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013; 158:329.</a></li><li><a class="nounderline abstract_t">Aleman S, Rahbin N, Weiland O, et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis 2013; 57:230.</a></li><li><a class="nounderline abstract_t">Singal AG, Dharia TD, Malet PF, et al. Long-term benefit of hepatitis C therapy in a safety net hospital system: a cross-sectional study with median 5-year follow-up. BMJ Open 2013; 3:e003231.</a></li><li><a class="nounderline abstract_t">Johnson RJ, Willson R, Yamabe H, et al. Renal manifestations of hepatitis C virus infection. Kidney Int 1994; 46:1255.</a></li><li><a class="nounderline abstract_t">Misiani R, Bellavita P, Fenili D, et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 1992; 117:573.</a></li><li><a class="nounderline abstract_t">Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327:1490.</a></li><li><a class="nounderline abstract_t">Johnson RJ, Gretch DR, Couser WG, et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 1994; 46:1700.</a></li><li><a class="nounderline abstract_t">Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330:751.</a></li><li><a class="nounderline abstract_t">Yamabe H, Johnson RJ, Gretch DR, et al. Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan. J Am Soc Nephrol 1995; 6:220.</a></li><li><a class="nounderline abstract_t">Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 1995; 332:1457.</a></li><li><a class="nounderline abstract_t">Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24:778.</a></li><li><a class="nounderline abstract_t">Casato M, Agnello V, Pucillo LP, et al. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 1997; 90:3865.</a></li><li><a class="nounderline abstract_t">Alric L, Plaisier E, Thébault S, et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis 2004; 43:617.</a></li><li><a class="nounderline abstract_t">Dammacco F, Sansonno D, Han JH, et al. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 1994; 84:3336.</a></li><li><a class="nounderline abstract_t">Saadoun D, Resche Rigon M, Thibault V, et al. Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Ann Rheum Dis 2014; 73:831.</a></li><li><a class="nounderline abstract_t">Ferri C, Marzo E, Longombardo G, et al. Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood 1993; 81:1132.</a></li><li><a class="nounderline abstract_t">Lunel F, Musset L, Cacoub P, et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology 1994; 106:1291.</a></li><li><a class="nounderline abstract_t">Casato M, Laganà B, Antonelli G, et al. Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia. Blood 1991; 78:3142.</a></li><li><a class="nounderline abstract_t">Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328:465.</a></li><li><a class="nounderline abstract_t">Dammacco F, Sansonno D. Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N Engl J Med 2013; 369:1035.</a></li><li><a class="nounderline abstract_t">Cornella SL, Stine JG, Kelly V, et al. Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: A case series. Postgrad Med 2015; 127:413.</a></li><li><a class="nounderline abstract_t">Urraro T, Gragnani L, Piluso A, et al. Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy. Case Reports Immunol 2015; 2015:816424.</a></li><li><a class="nounderline abstract_t">Stine JG, Cornella S, Shah NL. Treatment of chronic hepatitis C complicated by mixed cryoglobulinemia with new protease inhibitor, sofosbuvir. Ann Rheum Dis 2014; 73:e64.</a></li><li><a class="nounderline abstract_t">Sise ME, Bloom AK, Wisocky J, et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology 2016; 63:408.</a></li><li class="breakAll">www.HCVguidance.org.</li><li><a class="nounderline abstract_t">Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology 2015; 149:649.</a></li><li><a class="nounderline abstract_t">Pietrogrande M, De Vita S, Zignego AL, et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 2011; 10:444.</a></li><li><a class="nounderline abstract_t">Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010; 116:326.</a></li><li><a class="nounderline abstract_t">Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68:310.</a></li><li class="breakAll">National Kidney Foundation. GFR Calculator. https://www.kidney.org/professionals/kdoqi/gfr_calculator (Accessed on June 23, 2017).</li><li><a class="nounderline abstract_t">Gane E, Lawitz E, Pugatch D, et al. Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment. N Engl J Med 2017; 377:1448.</a></li><li class="breakAll">Gilead. Sofosbuvir for treatment of chronic hepatitis C infection. Briefing document prepared for the Antiviral Drugs Advisory Committee meeting. October 25, 2013. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/antiviraldrugsadvisorycommittee/ucm371877.pdf.</li><li class="breakAll">Epclusa (sofosbuvir and velpatasvir). US FDA approved product information. National Library of Medicine. www.dailymed.nlm.nih.gov.</li><li><a class="nounderline abstract_t">Borgia SM, Dearden J, Yoshida EM, et al. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. J Hepatol 2019; 71:660.</a></li><li><a class="nounderline abstract_t">Bhamidimarri KR, Czul F, Peyton A, et al. Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease. J Hepatol 2015; 63:763.</a></li><li><a class="nounderline abstract_t">He YL, Yang SJ, Hu CH, et al. Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis. Aliment Pharmacol Ther 2018; 47:526.</a></li><li><a class="nounderline abstract_t">Singh T, Guirguis J, Anthony S, et al. Sofosbuvir-based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series. Liver Int 2016; 36:802.</a></li><li><a class="nounderline abstract_t">Desnoyer A, Pospai D, Lê MP, et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol 2016; 65:40.</a></li><li><a class="nounderline abstract_t">Nazario HE, Ndungu M, Modi AA. Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR &lt;30 ml/min. Liver Int 2016; 36:798.</a></li><li><a class="nounderline abstract_t">Brown PR, Sadiq O, Weick A, et al. Acute Kidney Injury in Patients Undergoing Chronic Hepatitis C Virus Treatment With Ledipasvir/Sofosbuvir. Hepatol Commun 2018; 2:1172.</a></li><li><a class="nounderline abstract_t">Elmowafy AY, El Maghrabi HM, Mashaly ME, et al. High rate of acute kidney injury in patients with chronic kidney disease and hepatitis C virus genotype 4 treated with direct-acting antiviral agents. Int Urol Nephrol 2019; 51:2243.</a></li><li><a class="nounderline abstract_t">Saxena V, Koraishy FM, Sise ME, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int 2016; 36:807.</a></li><li><a class="nounderline abstract_t">Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015; 386:1537.</a></li><li><a class="nounderline abstract_t">Alric L, Ollivier-Hourmand I, Bérard E, et al. Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective. Kidney Int 2018; 94:206.</a></li><li><a class="nounderline abstract_t">Pockros PJ, Reddy KR, Mantry PS, et al. Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease. Gastroenterology 2016; 150:1590.</a></li><li class="breakAll">Daklinza (daclatasvir). US FDA approved product information. National Library of Medicine. Princeton, NJ: Bristol Myers Squibb Corp; July 2015,</li><li><a class="nounderline abstract_t">Lindahl K, Schvarcz R, Bruchfeld A, Ståhle L. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepat 2004; 11:84.</a></li><li><a class="nounderline abstract_t">Kamar N, Boulestin A, Selves J, et al. Factors accelerating liver fibrosis progression in renal transplant patients receiving ribavirin monotherapy for chronic hepatitis C. J Med Virol 2005; 76:61.</a></li><li><a class="nounderline abstract_t">Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis 1999; 19 Suppl 1:17.</a></li><li class="breakAll">Rebetol (ribavirin). US FDA approved product information. National Library of Medicine. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=04d2b6f4-bd9b-4871-9527-92c81aa2d4d0 (Accessed on May 15, 2014).</li><li class="breakAll">Copegus (ribavirin). US FDA approved product information. National Library of Medicine. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d370635f-5530-4d42-a019-d76b61639787 (Accessed on May 15, 2014).</li><li><a class="nounderline abstract_t">Zuckerman E, Keren D, Slobodin G, et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. J Rheumatol 2000; 27:2172.</a></li><li><a class="nounderline abstract_t">Bruchfeld A, Lindahl K, Ståhle L, et al. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 2003; 18:1573.</a></li><li><a class="nounderline abstract_t">Liu CH, Huang CF, Liu CJ, et al. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann Intern Med 2013; 159:729.</a></li><li class="breakAll">HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Joint panel from the American Association of the Study of Liver Diseases and the Infectious Diseases Society of America. http://www.hcvguidelines.org/ (Accessed on January 01, 2020).</li><li><a class="nounderline abstract_t">Martin P, Awan AA, Berenguer MC, et al. Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int 2022; 102:1228.</a></li><li><a class="nounderline abstract_t">Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014; 371:2375.</a></li><li class="breakAll">Manns M, et al.: Ledipasvir/Sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: Preliminary results of the prospective SOLAR 2 trial. Presented at the 50th Annual Meeting of the European Association for the Study of the Liver (EASL), Vienna Austria, April 22-26, 2015. Abstract G02</li><li><a class="nounderline abstract_t">Curry MP, O'Leary JG, Bzowej N, et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med 2015; 373:2618.</a></li><li><a class="nounderline abstract_t">Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349:931.</a></li></ol></div><div id="topicVersionRevision">Topic 93448 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21757949" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Treatment of hepatitis C-mediated glomerular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30496620" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The association of hepatitis C infection with the onset of CKD and progression into ESRD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20564351" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Outcome of sustained virological responders with histologically advanced chronic hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18025443" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23268517" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23460056" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23616492" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24002983" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Long-term benefit of hepatitis C therapy in a safety net hospital system: a cross-sectional study with median 5-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7853784" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Renal manifestations of hepatitis C virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1326246" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Hepatitis C virus infection in patients with essential mixed cryoglobulinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1383822" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A role for hepatitis C virus infection in type II cryoglobulinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7535369" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8107741" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7579088" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7739681" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8855176" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9354653" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15042538" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7524736" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23606708" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8382969" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7513667" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1742481" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7678440" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Membranoproliferative glomerulonephritis associated with hepatitis C virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24024840" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Therapy for hepatitis C virus-related cryoglobulinemic vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25746436" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25815218" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25038237" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Treatment of chronic hepatitis C complicated by mixed cryoglobulinemia with new protease inhibitor, sofosbuvir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26474537" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26474537" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25985734" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21303705" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20439619" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18413444" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : EULAR recommendations for the management of primary small and medium vessel vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18413444" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : EULAR recommendations for the management of primary small and medium vessel vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29020583" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29020583" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29020583" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31195062" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26095179" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29250808" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26824848" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Sofosbuvir-based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26952005" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26583882" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR&lt;30 ml/min.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30288472" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Acute Kidney Injury in Patients Undergoing Chronic Hepatitis C Virus Treatment With Ledipasvir/Sofosbuvir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31612423" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : High rate of acute kidney injury in patients with chronic kidney disease and hepatitis C virus genotype 4 treated with direct-acting antiviral agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26923436" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26456905" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29735308" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26976799" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26976799" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14738562" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15778976" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Factors accelerating liver fibrosis progression in renal transplant patients receiving ribavirin monotherapy for chronic hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10349689" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The clinical pharmacology of ribavirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10349689" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The clinical pharmacology of ribavirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10349689" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The clinical pharmacology of ribavirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10990230" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12897097" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24297189" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24297189" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36411019" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25386767" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : An interferon-free antiviral regimen for HCV after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25386767" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : An interferon-free antiviral regimen for HCV after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26569658" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12954741" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Chronic renal failure after transplantation of a nonrenal organ.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
